ISR - Radiopharmaceutical company Viewpoint to merge with Isoray

• Radiopharmaceutical company Viewpoint Molecular Targeting is set to merge with medical technology company Isoray ( NYSE: ISR ), subject to approval by the shareholders of both the companies.
• According to the definitive merger agreement, each issued and outstanding share of Viewpoint will be converted into the right to receive 3.3212 shares of Isoray.
• The Viewpoint stockholders will own 49% of the fully diluted outstanding capital stock of Isoray.
• The transaction will increase the size of Isoray's board to 5 with 2 directors to be designated by Viewpoint and 3 directors to be designated by Isoray.
• Isoray's Lori Woods will serve as the chairperson.
• Viewpoint CEO Thijs Spoor will be one of the directors and serve as Isoray's CEO.
• ISR shares were trading -2.67% pre-market.
• Source: Press Release

For further details see: